Teva Pharmaceutical Industries EBITDA Margin 2010-2025 | TEVA

Teva Pharmaceutical Industries ebitda margin for the quarter ending March 31, 2025 was 8.82%.

  • Teva Pharmaceutical Industries average ebitda margin for 2024 was 8.55%, a 311.06% increase from 2023.
  • Teva Pharmaceutical Industries average ebitda margin for 2023 was 2.08%, a 8.77% increase from 2022.
  • Teva Pharmaceutical Industries average ebitda margin for 2022 was 2.28%, a 214.57% decline from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Teva Pharmaceutical Industries EBITDA Margin 2010-2025 | TEVA

  • Teva Pharmaceutical Industries average ebitda margin for 2024 was 8.55%, a 311.06% increase from 2023.
  • Teva Pharmaceutical Industries average ebitda margin for 2023 was 2.08%, a 8.77% increase from 2022.
  • Teva Pharmaceutical Industries average ebitda margin for 2022 was 2.28%, a 214.57% decline from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
Dr Reddy's Laboratories (RDY)$11.4B
BridgeBio Pharma (BBIO)$6.4B
Bausch Health Cos (BHC)$1.9B
Supernus Pharmaceuticals (SUPN)$1.7B
Amphastar Pharmaceuticals (AMPH)$1.1B
Personalis (PSNL)$282M
Taysha Gene Therapies (TSHA)$254M
Assembly Biosciences (ASMB)$75M
Sol-Gel Technologies (SLGL)$15M
Evoke Pharma (EVOK)$3M
Teligent (TLGT)$0M